129 related articles for article (PubMed ID: 11377651)
21. Neoadjuvant docetaxel-based chemoradiation for resectable adenocarcinoma of the pancreas: New neoadjuvant regimen was safe and provided an interesting pathologic response.
Turrini O; Ychou M; Moureau-Zabotto L; Rouanet P; Giovannini M; Moutardier V; Azria D; Delpero JR; Viret F
Eur J Surg Oncol; 2010 Oct; 36(10):987-92. PubMed ID: 20828979
[TBL] [Abstract][Full Text] [Related]
22. Subsieve-size agarose capsules enclosing ifosfamide-activating cells: a strategy toward chemotherapeutic targeting to tumors.
Sakai S; Kawabata K; Tanaka S; Harimoto N; Hashimoto I; Mu C; Salmons B; Ijima H; Kawakami K
Mol Cancer Ther; 2005 Nov; 4(11):1786-90. PubMed ID: 16276000
[TBL] [Abstract][Full Text] [Related]
23. A multicenter phase II trial of S-1 with concurrent radiation therapy for locally advanced pancreatic cancer.
Ikeda M; Ioka T; Ito Y; Yonemoto N; Nagase M; Yamao K; Miyakawa H; Ishii H; Furuse J; Sato K; Sato T; Okusaka T
Int J Radiat Oncol Biol Phys; 2013 Jan; 85(1):163-9. PubMed ID: 22677367
[TBL] [Abstract][Full Text] [Related]
24. Survival analysis of veteran patients with pancreatic cancer.
Kim D; Zhu H; Nassri A; Mokdad A; Kukreja S; Polanco P; Huerta S; Ramzan Z
J Dig Dis; 2016 Jun; 17(6):399-407. PubMed ID: 27235863
[TBL] [Abstract][Full Text] [Related]
25. [Current standards in the treatment of pancreatic cancer].
Pelzer U; Riess H
Dtsch Med Wochenschr; 2015 Dec; 140(24):1813-6. PubMed ID: 26625229
[TBL] [Abstract][Full Text] [Related]
26. Endoscopic palliation for inoperable pancreatic cancer.
Das A; Sivak MV
Cancer Control; 2000; 7(5):452-7. PubMed ID: 11000615
[TBL] [Abstract][Full Text] [Related]
27. Necrotic, rather than apoptotic, cell death caused by cytochrome P450-activated ifosfamide.
Karle P; Renner M; Salmons B; Günzburg WH
Cancer Gene Ther; 2001 Mar; 8(3):220-30. PubMed ID: 11332993
[TBL] [Abstract][Full Text] [Related]
28. The prognostic role of time to diagnosis and presenting symptoms in patients with pancreatic cancer.
Gobbi PG; Bergonzi M; Comelli M; Villano L; Pozzoli D; Vanoli A; Dionigi P
Cancer Epidemiol; 2013 Apr; 37(2):186-90. PubMed ID: 23369450
[TBL] [Abstract][Full Text] [Related]
29. Long-Term Follow-Up of Allogeneic Hematopoietic Stem Cell Transplantation for Solid Cancer.
Omazic B; Remberger M; Barkholt L; Söderdahl G; Potácová Z; Wersäll P; Ericzon BG; Mattsson J; Ringdén O
Biol Blood Marrow Transplant; 2016 Apr; 22(4):676-681. PubMed ID: 26740375
[TBL] [Abstract][Full Text] [Related]
30. Results of regional chemotherapy using the aortic stop-flow technique in advanced pancreatic carcinoma.
Meyer F; Gebauer T; Grote R; Martens-Lobenhoffer J; Ridwelski K; Lippert H
Surg Today; 2006; 36(2):155-61. PubMed ID: 16440163
[TBL] [Abstract][Full Text] [Related]
31. Combined chemotherapy of murine mammary tumors by local activation of the prodrugs ifosfamide and 5-fluorocytosine.
Kammertoens T; Gelbmann W; Karle P; Alton K; Saller R; Salmons B; Günzburg WH; Uckert W
Cancer Gene Ther; 2000 Apr; 7(4):629-36. PubMed ID: 10811482
[TBL] [Abstract][Full Text] [Related]
32. Phase 1/2a, dose-escalation, safety, pharmacokinetic and preliminary efficacy study of intratumoral administration of BC-819 in patients with unresectable pancreatic cancer.
Hanna N; Ohana P; Konikoff FM; Leichtmann G; Hubert A; Appelbaum L; Kopelman Y; Czerniak A; Hochberg A
Cancer Gene Ther; 2012 Jun; 19(6):374-81. PubMed ID: 22498722
[TBL] [Abstract][Full Text] [Related]
33. [Up-to-date diagnosis and treatment of advanced pancreatic cancer].
Stieler JM; Oettle H
Dtsch Med Wochenschr; 2005 Sep; 130(38):2146-8. PubMed ID: 16172956
[TBL] [Abstract][Full Text] [Related]
34. Carcinoma of the pancreas--bypass versus resection?
Ong CL; Rauff A
J R Coll Surg Edinb; 1993 Jun; 38(3):149-51. PubMed ID: 7687675
[TBL] [Abstract][Full Text] [Related]
35. Combined modality therapy for stage II and stage III pancreatic carcinoma.
Kamthan AG; Morris JC; Dalton J; Mandeli JP; Chesser MR; Leben D; Cooperman A; Bruckner HW
J Clin Oncol; 1997 Aug; 15(8):2920-7. PubMed ID: 9256136
[TBL] [Abstract][Full Text] [Related]
36. Histopathological tumour viability after neoadjuvant chemotherapy influences survival in resected pancreatic cancer: analysis of early outcome data.
Townend P; de Reuver PR; Chua TC; Mittal A; Clark SJ; Pavlakis N; Gill AJ; Samra JS
ANZ J Surg; 2018 Mar; 88(3):E167-E172. PubMed ID: 28318082
[TBL] [Abstract][Full Text] [Related]
37. Very Early Onset Pancreatic Adenocarcinoma - Clinical Presentation, Risk Factors and Therapeutic Options.
Bunduc Ș; Iacob R; Costache R; Stoica B; Radu C; Gheorghe C
Chirurgia (Bucur); 2018; 113(3):405-411. PubMed ID: 29981672
[No Abstract] [Full Text] [Related]
38. Borderline and locally advanced pancreatic adenocarcinoma margin accentuation with intraoperative irreversible electroporation.
Kwon D; McFarland K; Velanovich V; Martin RC
Surgery; 2014 Oct; 156(4):910-20. PubMed ID: 25239345
[TBL] [Abstract][Full Text] [Related]
39. Irreversible electroporation in locally advanced pancreatic cancer: potential improved overall survival.
Martin RC; McFarland K; Ellis S; Velanovich V
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S443-9. PubMed ID: 23128941
[TBL] [Abstract][Full Text] [Related]
40. Concurrent Chemoradiotherapy Versus Chemotherapy Alone for Unresectable Locally Advanced Pancreatic Cancer: A Retrospective Cohort Study.
Choi Y; Oh DY; Kim K; Chie EK; Kim TY; Lee KH; Han SW; Im SA; Kim TY; Ha SW; Bang YJ
Cancer Res Treat; 2016 Jul; 48(3):1045-55. PubMed ID: 26511805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
